Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN versus TERAZOL 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN versus TERAZOL 7.
GYNE-LOTRIMIN vs TERAZOL 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Terconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This disruption increases membrane permeability and leads to fungal cell death.
Intravaginal: clotrimazole 500 mg vaginal tablet once or 200 mg vaginal tablet daily for 3 days or 1% vaginal cream 5 g daily for 7–14 days. Topical: clotrimazole 1% cream applied to affected area twice daily for 2–4 weeks.
Intravaginal: One full applicator (approximately 5 g of cream containing 40 mg of terconazole) inserted vaginally once daily at bedtime for 7 consecutive days.
None Documented
None Documented
The terminal elimination half-life of clotrimazole is approximately 3.5-4.9 hours. However, after topical application, systemic absorption is minimal, and local concentrations persist for hours to days at the site of action.
Terminal elimination half-life is approximately 7-10 hours; clinically, it allows for once-daily vaginal application, but systemic accumulation is minimal with vaginal dosing.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; renal excretion accounts for <1% of absorbed dose.
Primarily fecal (approximately 60%) as unchanged drug and metabolites; renal excretion accounts for about 20% (mostly metabolites).
Category C
Category C
Azole Antifungal
Azole Antifungal